Please login to the form below

Not currently logged in
Email:
Password:

tumours

This page shows the latest tumours news and features for those working in and with pharma, biotech and healthcare.

Neoantigen player Achilles gets OK for first clinical trial

Neoantigen player Achilles gets OK for first clinical trial

The number of cells is expanded and then delivered to the patient as a personalised cell therapy that in theory should target and destroy tumours without harming healthy tissues. ... These T cells are already programmed to invade and attack the tumour,

Latest news

More from news
Approximately 8 fully matching, plus 939 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    This encompasses approaches to detecting cancers earlier, including novel techniques such as liquid biopsies (aka circulating tumour DNA tests) and new companion diagnostics. ... Another key development is a rise in prospective lung cancer screening in

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Immunotherapies have revolutionised oncology.Their ability to target tumours and enhance the immune response has had a dramatic impact on the prognosis of some cancer patients. ... may guide the more rational design of clinical trials to improve immune

  • Deal Watch October 2018

    Endocyte’s lead clinical product is 177Lu‐PSMA‐617, which uses its proprietary drug conjugation technology to deliver Lutetium‐177 directly to tumours. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the

  • Cancer care – the power of new technologies Cancer care – the power of new technologies

    on the tumour type that they had, with brain cancer patients highlighting a significantly worse experience than for other tumour types.

More from intelligence
Approximately 0 fully matching, plus 70 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 30 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics